StockWatch
·

Navin Fluorine International Limited-$

BSE: 532504

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
789.83
+8.1%+32.6%
Expenditure
523.20
+10.0%+24.8%
Net Profit
204.57
+7.3%+52.7%
OPM %
32.26%
-3.01pp+2.93pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.00221.15442.30663.46884.61Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Margin beat + CDMO early, but capex makes this a Hold

margin beat · CDMO inflection · capex intensity

Result verdictFollow-upQ2 FY2706 Nov 20266 minMetals & Mining

Record growth & margin beat; CDMO at inflection point ahead

CDMO inflection · margin resilience · specialty chemicals scale

TranscriptDeep diveQ2 FY2706 Nov 20266 minMetals & Mining

Navin Fluorine Q2 FY27: consolidated PAT up 81% YoY to ₹269 Cr, margins top guidance

speciality chemicals · fluorochemicals · margin expansion

ResultsQ2 FY2730 Oct 20263 minMetals & Mining
Latest
Board Meeting30 Oct, 2:49 pm

Navin Fluorine Q2 FY27: consolidated PAT up 81% YoY to ₹269 Cr, margins top guidance

Navin Fluorine's consolidated revenue for Q2 FY27 (quarter ended September 30, 2026) came in at ₹1,190.74 Cr, up 57.0% YoY from ₹758.42 Cr and up 13.9% QoQ from ₹1,045.08 Cr. Consolidated PAT was ₹269.24 Cr, up 81.4% YoY from ₹148.37 Cr and up 10.7% QoQ from ₹243.31 Cr — profit growth continued to outrun revenue growth YoY, extending the pattern from Q1 FY27 (PAT +107.7% YoY). Basic EPS was ₹52.48 against ₹29.06 a year earlier. No exceptional items were recorded in either the current or year-ago quarter, so the growth is unadjusted/clean; the only one-off in the trailing record is a ₹6.75 Cr consolidated labour-code provision booked for the FY26 full year, outside both compared quarters. OPM (EBITDA/revenue from operations) expanded to 34.2% from 32.46% a year ago, and held essentially flat against Q1 FY27's 34.17% — sitting at or just above the top of management's own FY27 guided band of "normalized EBITDA margins 32-33% ±1%" set out on the August 2026 Q1 concall, meaning the quarter met to slightly beat that outlook. NPM was 22.3%, up sharply from 19.1% YoY but down marginally from 22.5% in Q1, as other income normalized to ₹15.6 Cr from ₹35.1 Cr in Q1. Standalone PAT was ₹204.57 Cr on standalone revenue of ₹737.26 Cr; the gap to consolidated PAT of ₹269.24 Cr (roughly ₹65 Cr, about a quarter of group profit) reflects contribution from the foreign subsidiaries and the CDMO/Advanced Sciences units the company has been directing capex toward. No separate management press release accompanied this filing beyond the regulatory board-outcome letter, so framing claims could not be cross-checked against company commentary; the relevant benchmark remains the FY27 margin band and CDMO targets from the Q1 concall, against which this quarter's 34.2% OPM is tracking at the top end. Public searches turned up no specific sell-side consensus estimate published for this exact quarter, so vsStreet is marked unknown rather than inferred — contemporaneous coverage had noted Q1 FY27 results "crushed Street estimates," and this quarter's growth cadence (revenue +57%, PAT +81% YoY) is broadly consistent with that trajectory continuing. The quarter also carried several corporate developments tying into the print: the board declared an ₹8/share interim dividend (400% of face value, record date November 5, 2026); the Honeywell HFC supply contract was extended to $590 Mn on October 29; and a subsidiary commissioned MPP debottlenecking capacity on September 29. Going into Q3 FY27, the markers to watch are whether the 34%+ OPM holds as the HFC/MPP/Chemours capex base scales further — management's own guided ceiling is 34%, so any further expansion would exceed its stated range — progress on the CDMO 3x asset-turn-by-FY29 target and the 3-4 FDA readouts flagged for the next 8-12 months, and whether other income normalizes further from this quarter's ₹15.6 Cr as NPM settles.

30 Oct 2026, 02:49 pm

Corporate Events

DividendNAVINFLUOR
2026
5Nov

₹8 / share

BSE Filing ↗
Board MeetingNAVINFLUOR
2026
30Oct

Board Meeting

The Board Meeting is scheduled to consider and approve the U…

BSE Filing ↗
Board MeetingNAVINFLUOR
2026
5Aug

Board Meeting

The meeting of the Board of Directors of the Company is sche…

BSE Filing ↗
DividendNAVINFLUOR
2026
30Jul

₹8.6 / share

BSE Filing ↗
Board MeetingNAVINFLUOR
2026
29Apr

Board Meeting

To consider, approve and take on record the Annual Audited S…

BSE Filing ↗
Board MeetingNAVINFLUOR
2026
9Feb

Board Meeting

consider, approve and take on record, the Unaudited Standalo…

BSE Filing ↗
DividendNAVINFLUOR
2025
7Nov

₹6.5 / share

BSE Filing ↗
DividendNAVINFLUOR
2025
30Oct

Dividend

BSE Filing ↗
Board MeetingNAVINFLUOR
2025
30Oct

Board Meeting

consider, approve and take on record, the Unaudited Standalo…

BSE Filing ↗
DividendNAVINFLUOR
2025
4Jul

₹7 / share

BSE Filing ↗
Board MeetingNAVINFLUOR
2025
9May

Board Meeting

Consider, approve and take on record, the Annual Audited Sta…

BSE Filing ↗
Board MeetingNAVINFLUOR
2025
8May

Board Meeting

Update on board meeting, Consider and approve fund raising

BSE Filing ↗
Board MeetingNAVINFLUOR
2025
30Jan

Board Meeting

consider, approve and take on record, the Unaudited Standalo…

BSE Filing ↗
DividendNAVINFLUOR
2024
7Nov

₹5 / share

BSE Filing ↗
Board MeetingNAVINFLUOR
2024
23Oct

Board Meeting

Consider, approve and take on record, the Unaudited Standalo…

BSE Filing ↗
Board MeetingNAVINFLUOR
2024
30Jul

Board Meeting

consider, approve and take on record, the Unaudited Standalo…

BSE Filing ↗
DividendNAVINFLUOR
2024
5Jul

₹7 / share

BSE Filing ↗
Board MeetingNAVINFLUOR
2024
29Jun

Board Meeting

fund raising proposal

BSE Filing ↗
Board MeetingNAVINFLUOR
2024
6Feb

Board Meeting

Consider and approve the Unaudited Standalone and Consolidat…

BSE Filing ↗
DividendNAVINFLUOR
2023
10Nov

₹25 / share

BSE Filing ↗